Endocrinol Metab:患者PRKACA L206R突变体产生皮质醇腺瘤的临床和分子特征

2022-01-20 从医路漫漫 MedSci原创

库欣综合征是内源性高皮质醇血症伴代谢、心血管和肌肉骨骼并发症的一种危急状态,需要手术或药物治疗。

库欣综合征是内源性高皮质醇血症伴代谢、心血管和肌肉骨骼并发症的一种危急状态,需要手术或药物治疗。非促肾上腺皮质激素(ACTH)依赖性库欣综合征或原发性肾上腺库欣综合征占内源性库欣综合征病例的20% - 30%,包括产生皮质醇腺瘤(CPA)和双侧小结节或大结节性肾上腺皮质增生

环磷酸腺苷(cAMP)依赖性蛋白激酶A (PKA)信号通路在ACTH依赖性库欣综合征中起重要作用。原发性色素沉着结节性肾上腺疾病可能是散发性的,也可能是Carney复合物的一部分,其原因是PRKAR1A (PKA的一个调节单元)或11A磷酸二酯酶(PDE11A)的生殖系失活性突变。此外,研究还发现,鸟嘌呤核苷酸结合蛋白α刺激(GNAS)的激活生殖系突变与McCune-Albright综合征的CPAs相关,该突变编码刺激g蛋白α亚基。

蛋白激酶cAMP激活催化亚基α(PRKACA)的一个激活突变(c.617A>C/p.Lys206Arg,L206R)在35%到65%的皮质醇产生腺瘤(CPA)中被报道。我们的目的是比较韩国PRKACA L206R突变株和野生型CPA的临床特征和转录组分析。

方法:57例CPA患者在首尔国立大学医院接受肾上腺切除术。对57例CPA肿瘤组织进行PRKACA基因Sanger测序。对13例新鲜冷冻肿瘤组织进行RNA测序。

结果:PRKACA L206R突变的发生率为51%(29/57)。研究对象的平均年龄为42±12岁,87.7%(50/57)的患者为女性。与野生型CPA相比,携带PRKACA L206R突变型CPA的患者腺瘤体积(3.33±0.7cmvs.3.8±1.2cmvs.3.8±1.2 cm,P=0.059)和硫酸脱氢表雄酮水平(218.1±180ngmLvs.1511±3307 ng/mL,P=0.001)明显降低。转录组分析发现PRKACA L206R突变体(n=8)和野生型CPA(n=5)间差异表达基因2 44个,其中PRKACA L2 0 6R突变型CPA中上调基因5个,下调基因2 39个(|倍数变化|≥2,P<0.0 5)。在DEGS的上游调控因子中,CTNNB1是最重要的转录调控因子。在几个途径分析中,Wnt信号通路在PRKACA突变体中下调,类固醇生物合成途径上调。蛋白质-蛋白质相互作用分析还表明,PRKACA下调Wnt信号,上调类固醇生物合成。

表1 根据PRKACA体细胞突变状态研究对象的临床和生化特征

图 蛋白激酶camp激活的催化亚基α (PRKACA) L206R突变体与野生型皮质醇生成腺瘤(CPAs)的差异表达基因(DEGs)分析(A) DEGs的V火山图,x轴为PRKACA L206R突变体与野生型CPAs基因表达差异的幅度,y轴为差异的统计学意义。(B) t-分布随机邻居嵌入(tSNE)图。FC,褶皱变化。

表2 PRKACA L206R突变体与野生型产生皮质醇腺瘤的主要差异表达基因(|FC|≥2,P<0.05)

结论:转录组分析支持,CPAS中PRKACA L206R突变导致激素活性增高和增殖能力有限。

原文出处:Jang I,  Kim SJ,  Song RY,et al.Clinical and Molecular Characteristics of PRKACA L206R Mutant Cortisol-Producing Adenomas in Korean Patients.Endocrinol Metab (Seoul) 2021 Dec 02

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1888400, encodeId=eaed188840008, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Fri Feb 18 07:13:51 CST 2022, time=2022-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896969, encodeId=161d189696988, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed Aug 31 20:13:51 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771455, encodeId=fcb91e714555c, content=<a href='/topic/show?id=655b31640c7' target=_blank style='color:#2F92EE;'>#分子特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31640, encryptionId=655b31640c7, topicName=分子特征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=197038292186, createdName=zlawrance, createdTime=Mon Aug 08 18:13:51 CST 2022, time=2022-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652003, encodeId=2a471652003fe, content=<a href='/topic/show?id=3a3e1e9504' target=_blank style='color:#2F92EE;'>#ACA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1795, encryptionId=3a3e1e9504, topicName=ACA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=843c24278901, createdName=lishizhe, createdTime=Thu Apr 14 13:13:51 CST 2022, time=2022-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277828, encodeId=befc12e7828b6, content=<a href='/topic/show?id=e9f2e2180ef' target=_blank style='color:#2F92EE;'>#皮质醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72180, encryptionId=e9f2e2180ef, topicName=皮质醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Tue Jan 18 07:13:51 CST 2022, time=2022-01-18, status=1, ipAttribution=)]
    2022-02-18 guojianrong
  2. [GetPortalCommentsPageByObjectIdResponse(id=1888400, encodeId=eaed188840008, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Fri Feb 18 07:13:51 CST 2022, time=2022-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896969, encodeId=161d189696988, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed Aug 31 20:13:51 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771455, encodeId=fcb91e714555c, content=<a href='/topic/show?id=655b31640c7' target=_blank style='color:#2F92EE;'>#分子特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31640, encryptionId=655b31640c7, topicName=分子特征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=197038292186, createdName=zlawrance, createdTime=Mon Aug 08 18:13:51 CST 2022, time=2022-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652003, encodeId=2a471652003fe, content=<a href='/topic/show?id=3a3e1e9504' target=_blank style='color:#2F92EE;'>#ACA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1795, encryptionId=3a3e1e9504, topicName=ACA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=843c24278901, createdName=lishizhe, createdTime=Thu Apr 14 13:13:51 CST 2022, time=2022-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277828, encodeId=befc12e7828b6, content=<a href='/topic/show?id=e9f2e2180ef' target=_blank style='color:#2F92EE;'>#皮质醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72180, encryptionId=e9f2e2180ef, topicName=皮质醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Tue Jan 18 07:13:51 CST 2022, time=2022-01-18, status=1, ipAttribution=)]
    2022-08-31 一闲
  3. [GetPortalCommentsPageByObjectIdResponse(id=1888400, encodeId=eaed188840008, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Fri Feb 18 07:13:51 CST 2022, time=2022-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896969, encodeId=161d189696988, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed Aug 31 20:13:51 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771455, encodeId=fcb91e714555c, content=<a href='/topic/show?id=655b31640c7' target=_blank style='color:#2F92EE;'>#分子特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31640, encryptionId=655b31640c7, topicName=分子特征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=197038292186, createdName=zlawrance, createdTime=Mon Aug 08 18:13:51 CST 2022, time=2022-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652003, encodeId=2a471652003fe, content=<a href='/topic/show?id=3a3e1e9504' target=_blank style='color:#2F92EE;'>#ACA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1795, encryptionId=3a3e1e9504, topicName=ACA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=843c24278901, createdName=lishizhe, createdTime=Thu Apr 14 13:13:51 CST 2022, time=2022-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277828, encodeId=befc12e7828b6, content=<a href='/topic/show?id=e9f2e2180ef' target=_blank style='color:#2F92EE;'>#皮质醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72180, encryptionId=e9f2e2180ef, topicName=皮质醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Tue Jan 18 07:13:51 CST 2022, time=2022-01-18, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1888400, encodeId=eaed188840008, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Fri Feb 18 07:13:51 CST 2022, time=2022-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896969, encodeId=161d189696988, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed Aug 31 20:13:51 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771455, encodeId=fcb91e714555c, content=<a href='/topic/show?id=655b31640c7' target=_blank style='color:#2F92EE;'>#分子特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31640, encryptionId=655b31640c7, topicName=分子特征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=197038292186, createdName=zlawrance, createdTime=Mon Aug 08 18:13:51 CST 2022, time=2022-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652003, encodeId=2a471652003fe, content=<a href='/topic/show?id=3a3e1e9504' target=_blank style='color:#2F92EE;'>#ACA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1795, encryptionId=3a3e1e9504, topicName=ACA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=843c24278901, createdName=lishizhe, createdTime=Thu Apr 14 13:13:51 CST 2022, time=2022-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277828, encodeId=befc12e7828b6, content=<a href='/topic/show?id=e9f2e2180ef' target=_blank style='color:#2F92EE;'>#皮质醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72180, encryptionId=e9f2e2180ef, topicName=皮质醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Tue Jan 18 07:13:51 CST 2022, time=2022-01-18, status=1, ipAttribution=)]
    2022-04-14 lishizhe
  5. [GetPortalCommentsPageByObjectIdResponse(id=1888400, encodeId=eaed188840008, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Fri Feb 18 07:13:51 CST 2022, time=2022-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1896969, encodeId=161d189696988, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Wed Aug 31 20:13:51 CST 2022, time=2022-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771455, encodeId=fcb91e714555c, content=<a href='/topic/show?id=655b31640c7' target=_blank style='color:#2F92EE;'>#分子特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31640, encryptionId=655b31640c7, topicName=分子特征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=197038292186, createdName=zlawrance, createdTime=Mon Aug 08 18:13:51 CST 2022, time=2022-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652003, encodeId=2a471652003fe, content=<a href='/topic/show?id=3a3e1e9504' target=_blank style='color:#2F92EE;'>#ACA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1795, encryptionId=3a3e1e9504, topicName=ACA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=843c24278901, createdName=lishizhe, createdTime=Thu Apr 14 13:13:51 CST 2022, time=2022-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277828, encodeId=befc12e7828b6, content=<a href='/topic/show?id=e9f2e2180ef' target=_blank style='color:#2F92EE;'>#皮质醇#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72180, encryptionId=e9f2e2180ef, topicName=皮质醇)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c279140, createdName=vividelife, createdTime=Tue Jan 18 07:13:51 CST 2022, time=2022-01-18, status=1, ipAttribution=)]